Article
Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non-small-cell Lung Cancer: Study Protocol for an Open-label Randomized Controlled Trial.
Clinical lung cancer - 1 Mar 2021
Ma Jia, Pi Guoliang, Bi Jianping, Li Ying, He Hanping, Li Yanping, Hu Desheng, Verma Vivek, Han Guang
Abstract excerpt
Brain radiotherapy (BR) is a well-recognized approach for multiple brain metastases (BMs) from non-small-cell lung cancer (NSCLC). However, the prognosis for these patients remains poor. Apatinib, an antiangiogenic agent targeting vascular endothelial growth factor receptor-2, has shown excellent efficacy in multiple solid tumors. This phase II (WWW. ClinicalTrials.gov Identifier: VEGFR-2 NCT03801200) randomized...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.